ARCTArcturus Therapeutics Holdings Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $15.60 · now $15.60 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ARCT has typically landed between $10.71 and $21.98 — a range of −31.3% to +40.9% from the issuance price $15.60.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,328 overlapping 1 month windows · 2013-05-222026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($15.60) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ARCT has typically landed a month from the 2026-09-16 close of $15.6 — the range is history, not a prediction.

$10.71worst · -31.3%$21.98best · +40.9%
  • now $15.6 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $15.3 (-1.9%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $13.15$17.46
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $10.71$21.98
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,328 windows spanning 2013-05-22 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2014-09-26−81.9%−81.9%+0.0%
2014-09-25−80.7%−80.7%+3.8%
2014-09-24−78.9%−78.9%+0.0%
3 best
2020-04-01+222.7%+0.0%+222.7%
2020-04-09+219.0%+0.0%+219.0%
2020-04-06+213.5%+0.0%+213.5%

3,328 overlapping windows · 2013-05-222026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~14 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
54%
+8.5%
n=13
Feb
54%
+1.7%
n=13
Mar
23%
−5.1%
n=13
Apr
62%
+11.1%
n=13
May
54%
+8.1%
n=13
Jun
57%
+1.2%
n=14
Jul
50%
+7.9%
n=14
Aug
57%
+17.9%
n=14
Sep
43%
−4.5%
n=14
Oct
38%
−7.8%
n=13
Nov
62%
+3.4%
n=13
Dec
31%
−6.5%
n=13

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$23$62025-08-15: 1 insider purchase, $20K — SASSINE ANDY2025-08: 1 open-market purchase, $20K↑ buys↓ salesdirector SASSINE ANDY — Purchase on 2025-08-15, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-08-15SASSINE ANDYdirectorPurchase1,238 @ $16.56$20K−0.6% of holding−9.7%−68.7%221,764Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

23 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-05HOLMES EDWARD WdirectorAward / grant15,00015,000Form 4
2026-06-05Marantz Jing L.directorAward / grant15,00015,000Form 4
2026-06-05Marquet MagdadirectorAward / grant15,00015,000Form 4
2026-06-05Slaoui MoncefdirectorAward / grant15,00015,000Form 4
2026-06-05Markels JohndirectorAward / grant15,00015,000Form 4
2026-06-05BARLOW JAMES FdirectorAward / grant15,00015,000Form 4
2026-06-05FARRELL PETER CdirectorAward / grant15,00015,000Form 4
2026-05-01MULROY DENNISofficerAward / grant100,000100,000Form 4
2025-12-17Payne Joseph EdirectorAward / grant175,000175,000Form 4
2025-12-17Chivukula PadofficerAward / grant54,00054,000Form 4
2025-12-17Kurata LanceofficerAward / grant54,00054,000Form 4
2025-12-17Roberts JosephofficerAward / grant10,00010,000Form 4
2025-06-09HOLMES EDWARD WdirectorAward / grant15,00015,000Form 4
2025-06-09BARLOW JAMES FdirectorAward / grant15,00015,000Form 4
2025-06-09Slaoui MoncefdirectorAward / grant15,00015,000Form 4
2025-06-09FARRELL PETER CdirectorAward / grant15,00015,000Form 4
2025-06-09Marantz Jing L.directorAward / grant15,00015,000Form 4
2025-06-09Markels JohndirectorAward / grant15,00015,000Form 4
2025-06-09Marquet MagdadirectorAward / grant15,00015,000Form 4
2024-12-16Chivukula PadofficerAward / grant60,00060,000Form 4
2024-12-16SASSINE ANDYdirectorAward / grant60,00060,000Form 4
2024-12-16Payne Joseph EdirectorAward / grant196,000196,000Form 4
2024-12-16Kurata LanceofficerAward / grant60,00060,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.